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Abstract
Since the first reports of AIDS, skin involvement has become a burdensome stigma for seropositive patients and a
challenging task for dermatologist and infectious disease specialists due to the severe and recalcitrant nature of
the conditions. Dermatologic manifestations in AIDS patients act as markers of disease progression, a fact that
enhances the importance of understanding their pathogenesis.
Broadly, cutaneous disorders associated with HIV type-1 infection can be classified as primary and secondary. While
the pathogenesis of secondary complications, such as opportunistic infections and skin tumours, is directly
correlated with a decline in the CD4
+ T cell count, the origin of the certain manifestations primarily associated with
the retroviral infection itself still remains under investigation.
The focus of this review is to highlight the immunological phenomena that occur in the skin of HIV-1-seropositive
patients, which ultimately lead to skin disorders, such as seborrhoeic dermatitis, atopic dermatitis, psoriasis and
eosinophilic folliculitis. Furthermore, we compile the latest data on how shifts in the cytokines milieu, impairments
of the innate immune compartment, reactions to xenobiotics and autoimmunity are causative agents in HIV-1-
driven skin diseases. Additionally, we provide a thorough analysis of the small animal models currently used to
study HIV-1-associated skin complications, centering on transgenic rodent models, which unfortunately, have not
been able to fully unveil the role of HIV-1 genes in the pathogenesis of their primarily associated dermatological
manifestations.
Review
More than 25 years have passed since the first reports
on AIDS, and we are still unable to fully understand the
complexity of this disease. Dermatologic disorders play a
unique role in the HIV-1/AIDS spectrum, as almost all
seropositive patients suffer from these debilitating and
often disfiguring lesions [1]. Cutaneous disorders asso-
ciated with HIV-1/AIDS undermine self-esteem and
induce depression, conditions that put patients at high
risk of suicide.
Since the description of Kaposi’s sarcoma as an AIDS-
related condition, 56 other cutaneous disorders have
been linked to HIV-1/AIDS [2]. Although the introduc-
tion of highly active antiretroviral therapy (HAART) sig-
nificantly decreased the prevalence of opportunistic
infections and Kaposi’s sarcoma, the prevalence of most
inflammatory conditions primarily related to HIV-1
remains constant [3,4]. Nevertheless, while most of
these dermatological manifestations directly associated
with HIV-1/AIDS are currently considered as markers
of disease progression, the pathogenesis of some of
them is not completely understood yet [5]. Recent
explanations about the pathogenesis of these disorders
suggest that not only the decline in CD4
+ T cell counts
[6], but also the shift into a Th2 cytokine profile [7], the
molecular mimicry [8] and the over-expression of super-
antigens/xenobiotics [9], play a decisive role in the
development of dermatological lesions in the context of
HIV-1 infection.
Importantly, there is still a lack of conclusive evi-
dence linking HIV-1-associated gene products to the
pathogenesis of primary dermatological disorders seen
in AIDS patients. This fact derives from multiple fac-
tors that include: (1) the shortage on biosafety level 3
(BSL-3) facilities and BSL-3-trained individuals; (2) the
expenses associated with non-human primate studies;
and (3) the lack of small animal models to study
this particular disease. In order to overcome the
latter, many groups, including ours, have created trans-
genic rodent models (rat and mouse) for the study of
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these has successfully reproduce the data obtained
from AIDS patients [10-14]. This report compiles the
most recent data on the pathogenesis of inflammatory
cutaneous pathology directly associated with HIV-1
infection, and discusses the reasons why transgenic
animal models have failed to fully unveil the origin of
many complications seen in AIDS patients.
General immunologic cutaneous changes in the patient
with HIV-1 infection
The skin is the largest and most visible organ in the
body, and consequently presents the most numerous
and miscellaneous types of pathological manifestations.
The cutaneous immune system is unique in the fact that
it contains two types of antigen-presenting cells: the
Langerhans cells; and the dermal dendritic cells [15].
Both subsets of cells perform a coordinated series of
events upon antigen encounter, resulting in the presen-
tation of processed antigens to naïve T cells in the
draining lymph nodes. Once activated, T cells undergo
clonal expansion and home to specific sites where their
expression of effector soluble factors (cytokines and che-
mokines) orchestrates a coordinated contention of viral,
bacterial, fungal, parasitic or neoplastic invasion [16].
In HIV-1-seropositive patients, the aforementioned
process is abrogated in many ways. AIDS patients exhi-
bit a marked decrease in the number and function of
Langerhans cells, CD4
+, NK cells, macrophages and
monocytes [17-20] (Figure 1). While the final outcome
of HIV-1 infection is the decrease in these cell types,
the mechanisms by which HIV performs such lytic
activities still remains controversial. Pope et al [21]
showed that physical contact between HIV-1-pulsed
dendritic cells and CD4
+ T cells in the context of anti-
gen presentation promotes massive replication of the
virus with a cytolytic outcome to both cells types. More-
over, the compromise of the skin-associated immune
system is so critical that delayed-type hypersensitivity
tests now commonly serve as monitors for the progres-
sion of the disease [22]. As a consequence of such
decline in the number of antigen-presenting and CD4+
T cells, the skin becomes vulnerable to numerous
opportunistic infectious agents and neoplastic disorders;
Figure 1 HIV-1-driven immunological changes in the skin. Graphic representation of the immunological processes involved in the
pathogenesis of primary HIV-1 related skin disorders, highlighting the presentation of the virus by a dendritic cell to a CD4+ T lymphocyte and
the subsequent changes in the cytokine profile that are brought by the death of Th1 cells.
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describing the pathogenesis of the inflammatory condi-
tions related primarily to HIV-1 infection.
The clinical picture
The description of skin manifestations in HIV-1/AIDS
patients is complex and ranges from acne vulgaris to
Kaposi’s sarcoma. A brief classification of the most com-
mon dermatologic disorders in HIV-1/AIDS patients is
depicted below and categorizes the spectrum of diseases
in two groups: primary HIV-1-related skin disorders;
and secondary mucocutaneous signs of HIV-1 infection
(Table 1).
Noteworthy, secondary manifestations of HIV-1 infec-
tion are more prevalent than primary ones. For example,
in Africa, the most prevalent skin disorder in HIV-1/
AIDS patients is prurigo nodularis [23-25], a pruritic
condition associated with insect bites [26]. In several
other countries, mucocutaneous candidiasis and herpes
zoster infections are the leading cause of skin disorders
in these patients [27,28].
Nevertheless, a decline of certain skin disorders in
HIV-1/AIDS patients has already been observed ever
since HAART became more accessible to HIV-1/AIDS
patients [29]. Normal CD4
+ lymphocyte counts reduce
the chances of suffering from co-infectious and neoplas-
tic disorders [3]. Moreover, in developed countries,
where most people have access to HAART, dermatolo-
gic conditions, such as Kaposi’s sarcoma, prurigo nodu-
laris, molluscum, and photodermatitis, are becoming
rare [3,4].
However, the prevalence of most cutaneous disorders
associated primarily with HIV-1 infection, as well as
adverse drug reactions, have not changed in the pre-
sence of HAART [4]. This fact enhances the importance
of studying the pathogenesis of these disorders in order
to develop superior forms for their treatment.
HIV-1-associated primary dermatologic disorders
Seborrheic dermatitis
This is an entity characterized by erythema and scaling
of the central part of the face, involving nasolabial
folds and eyebrows, as well as the scalp [30] (Figure
2A). It is found in up to 40% of seropositive patients
[30] and in up to 80% of patients with AIDS compared
with 3% of the seronegative population [31,32]. Berger
and Greene in 1991 [33] reported that this condition
could be a hypersensitivity reaction to Pityrosporum
yeasts, but its association is still doubtful (Figure 1).
However, recent studies have failed to demonstrate any
fungal overgrowth [34] or a rise in the levels of IgG
titers against the yeast in HIV-1-seropositive patients
[35,36].
Histologically, the lesions of seborrheic dermatitis in
patients without HIV-1 show spongiform features, and
with time they become less spongiotic and develop folli-
cular plugs of orthokeratotic and parakeratotic cells, and
uneven rete ridges [37] (Figure 2B). Skin biopsy speci-
mens taken from lesions of AIDS patients show
widespread parakeratosis, keratocytic necrosis, leukoexo-
cytosis and superficial perivascular infiltrate of plasma
cells [38]. These sections also show expression of heat-
shock proteins (HSP65 and HSP72), a phenomenon that
does not occur in HIV-1-negative patients [39]. Sebor-
rheic dermatitis has been linked to depression of T cell
function, and in patients with HIV-1 infection, it
Table 1 Classification of HIV-1-related skin pathology
Primary Manifestations Secondary Manifestations
Infectious Neoplastic
○ Seborrheic dermatitis ○ Herpes simplex ○ Kaposi’s sarcoma
○ Xerosis ○ Varicella-Zoster ○ T cell lymphoma
○ Atopic dermatitis ○ HPV infection ○ Basal cell carcinoma
○ Eosinophilic folliculitis ○ Molluscum contagiosium ○ Squamous cell carcinoma
○ Psoriasis ○ S. Aureus infections
○ HIV-1-related pruritus - Folliculitis
○ Drug induced - Bullous impetigo
- Ecthyma
○ Mycobacterial cutaneous infection
○ Bacillary angiomatosis
○ P. Aeruginosa cutaneous infection
○ Candidiasis
○ Dermatophyte infection
○ Histoplasmosis
○ Criptococosis
○ Pneumocystis
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Page 3 of 11Figure 2 HIV-1 primary skin disorders. A) Patient with seborrheic dermatitis showing a papulosquamous disorder patterned on the sebum-
rich areas of the scalp and face. B) Representative section (H&E 20x) shows focal parakeratosis, moderarte acanthosis, spongiosis related to hair
follicles and scarce neutrophils. C) Patient with atopic dermatitis with lesions ranging from weeping crusted areas to lichenified plaques. D)
Representative section (H&E 20x) shows acanthosis, mild spongiosis, and dermal infiltrate composed of lymphocytes, monocytes and few
eosinophils. E) Patient with psoriasis, characterized by symmetric raised inflamed lesions covered with a silvery white scale in both lower limbs. F)
Representative section (H&E 10x) shows hyperkeratosis, parakeratosis, acanthosis, spongiosis, absence of granulosum layer and neutrophil
infiltrates (Munro’s microabscess). G) Patient with eosinophilic folliculitis featured by follicular pustular papules on the upper part of the chest. H)
Representative section (H&E 20x) shows perifollicular and perivascular infiltrate with eosinophils.
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+ lym-
phocyte count declines. Thus, it can be used as a marker
for disease progression [5,40].
Xerosis
Dryness of the skin is one of the most common skin
manifestations found in patients with HIV-1 infection.
This condition is found in more than 20% of people
with HIV-1 [41]. It presents mainly on extremities, and
it denotes one of the main causes of pruritus in AIDS
patients [42]. Its pathogenesis has been suggested to
include changes in the microcirculation, the nutrient
supply of the skin, and in the production of sweat and
oil in the skin [43]. Xerosis has also been related to cer-
tain effects on the mast cell population of the skin and
to the decreased skin innervation caused by AIDS
[43,44]. Reports show that such substances as calcitonin
gene-related peptide and such mediators as substance P
are decreased in the skin of these patients [45] (Figure 1).
Xerosis has been taken by several authors as a marker for
progression as it also correlates with CD4+ T lymphocyte
count decline [46].
Atopic dermatitis
This chronic inflammatory skin condition is seen in
approximately 30% to 50% of HIV-1/AIDS patients
(Figure 2.C) [43,47] compared with 2% to 20% of the sero-
negative population [48]. This is a pruritic disorder
mediated by Th2 cytokines, whose morphological features
include acanthosis and spongiosis, as well as cellular infil-
trates composed of lymphocytes, monocytes and eosino-
phils (Figure 2.D). The pathogenesis of this disorder has
been linked to hypereosinophilia and to high levels of IgE
secondary to Th1-Th2 imbalance [49]. Changes in cuta-
neous innervation and peptidergic neurotransmitters have
also been related to this disease [50].
A study performed of 74 patients with atopic dermati-
tis showed that 53% were colonized by toxic-shock-
syndrome toxin I produced by S. aureus [9]. These
superantigens penetrate the skin and bind to Langerhans
cells, thereby stimulating the release of IL-4 and IL-5,
which further enhance the production of the allergen-
specific IgE response [51]. Broadly, atopic dermatitis is
thought to be initiated in predisposed individuals by a
Th2 dominant cytokine production that enhances IgE
release [52] (Figure 1). This Th1/Th2 cytokine imbal-
ance is practically seen in all AIDS patients, specially in
later stages, when this situation predisposes atopic man-
ifestations [53].
Psoriasis
This is a chronic inflammatory skin disorder of pre-
sumed autoimmune origin found in 2% of the general
population [54]. The cause of psoriasis is still under
debate, but it is generally accepted to have a genetic
hereditary component, and a hyperproliferative epider-
mal nature driven by activated lymphocytes [55]. The
prevalence of psoriasis in HIV-1-seropositive individuals
is similar to that of their seronegative counterparts [56].
However, psoriatic lesions in AIDS patients tend to be
more severe, acral, extensive, destructive and recalcitrant
[54,57] (Figures 2E and 2F). Of note, the prevalence of
psoriatic arthritis is greatly increased in the HIV-1/AIDS
population compared with its immunocompetent coun-
terpart [58].
The pathogenesis of psoriasis in the context of HIV-1
infection has been associated with many immunologic
events that include a decrease in the number of Lan-
gherhan’s cells, but also with a potential epidermal pro-
liferative effect of HIV-1 itself, an altered CD8:CD4 ratio
and high synthesis of nitric oxide driven by HIV-1 in
macrophages [56]. This association has actually led to
an obscure hypothesis involving psoriasis and psoriatic
arthritis with a retroviral background [59,60].
In fact, in patients with known risk for HIV-1 expo-
sure, new onset of psoriasis may sometimes be a marker
of HIV-1 infection [61]. A full comparative analysis
between HIV-1-related and HIV-1-negative psoriasis is
depicted in Table 2.
Expanding on the pathogenesis of psoriasis, the causa-
tive trigger of the lymphocytic activation remains
unknown; however, self-antigens may play a significant
role in breaking the peripheral tolerance [69]. Recently,
there is growing evidence that links certain conditions
of autoimmune origin to human endogenous retro-
viruses (HERVs) [8,70]. HERVs are genomic sequences
that use reverse transcriptase and that can move from
one chromosomal site to another, belonging to a class
of parasitic elements that represent as much as 40% of
the mammalian genome [71].
These elements were integrated into our genome mil-
lion of years ago, when exogenous retroviruses infected
germ cells; once integrated, these sequences were trans-
mitted vertically as mutations of essential genes in a
mendelian fashion [70]. Retrovirologists often refer to
HERVs as defective proviruses with accumulated dele-
tions, frame shift mutations, or with stop codons in gag,
pol or env open reading frames, that limit their infec-
tious capacity [8]. The activation of these dormant
sequences of the genome has been linked to the patho-
genesis of several autoimmune diseases, including most
of the chronic arthropathies and systemic lupus erythe-
matosus [72,73]. Several HERVs are expressed in normal
peripheral blood lymphocytes [74], keratinocytes [75]
and many other tissues [76].
Notably, the hypothesis associating HERVs with psor-
iasis resulted from the detection of viral-like particles
resembling murine C-type retrovirus in psoriatic plaques
in 1983 [77]. The microscopic findings were further sup-
ported by the detection of p27, a retrovirus-like particle
in skin and lymphocytes from psoriatic patients [78,79],
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titers of IgG anti-murine leukaemia virus antibodies in
serum from patients with psoriasis when compared with
a healthy control [80].
A reasonable explanation of this association involves
molecular mimicry as the main phenomenon [70]. In
the context of viral infection, similarities between viral
amino acids and those found in host proteins lead to an
autoimmune reaction mediated either by T lymphocytes
or auto-antibodies that may last even after resolution of
the viral infection (Figure 3) [81]. Activation of HERVs
not only depend on retroviral infection, but they can
also by activated in the presence of ultraviolet light or
certain chemicals [69].
Recently, sequences of three different families of
HERVs have been identified in psoriatic lesions [69].
Sequences of families W,E,K, and a new sequence of the
ERV-9/HERV-W family were identified by the use of
reverse transcriptase-polymerase chain reaction. This
sequence contains at least two open reading frames that
could encode for a gag protein and a retroviral protease.
The expression of this sequence was detected in 29 of
43 lesional psoriasis skin samples, and in only two of 21
of normal skin samples [69]. Supporters of this theory
consider Koebner’s phenomenon as the result from the
damage of keratinocytes that expose viral proteins to
the immune system [70].
In addition, Mallon et al have suggested HIV-1-asso-
ciated immune dysregulation as a possible trigger of
psoriasis in those patients carrying the HLA-Cw0602
alele [62]. The HLA-Cw0602 alele might be a target for
CD8 lymphocytes responding to processed peptides pre-
sented in the context of major histocompatibility com-
plex-1, strengthening the argument for an important
role for CD8 T lymphocytes in the immunopathogenesis
of psoriasis.
Eosinophilic folliculitis
This is a cutaneous manifestation almost exclusively related
to HIV-1 infection, particularly in late stages of AIDS. It
was first described in 1986 [82] as a different entity from
Ofuji’s disease (pruritic follicular papules and pustules that
involve palms and soles). Eosinophilic folliculitis (EF) pre-
sents with increased serum IgE levels, eosinophlia and per-
ipheral leukocytosis; palms and soles are spared [83]. The
most common presentation of EF is an erythematous urti-
carial papular rash with some pinpoint vesicles or pustules
Table 2 Comparison between HIV-1 seronegative psoriasis and HIV-1 related psoriasis
Variable HIV-1-seronegative psoriasis HIV-1-related psoriasis References
Frequency 1-3% Similar to HIV-seronegative
population
[54,55]
Severity Mild-moderate Moderate-severe [62]
Clinical features Erythematous plaques usually circumscribed to
elbows-knees (psoriasis vulgaris)
More extensive lesions
Increased presence of acral
lesions and inverse psoriasis
[4,55]
Histhopatological features Hyperproliferation and hyperkeratosis, lymphocytic
infiltrate and absence of granular layer
Same [55]
Presence of psoriatic arthritis 5-20% 23%-50% [54,55]
Mean age of presentation >30 years =30 years [63]
Family history Frequent Variable [64]
Presence of HLA-Cw*0602 25% 79% [64]
Presence of Reiter’s Syndrome Rare Frequent [54]
Development of erythroderma +/+++ ++/+++ [65]
Response to conventional treatment (topical
steroids, Vitamin D analogues, phototherapy)
Variable Variable-poor [63,66]
Response to zidovudine/HAART +/+++ ++/+++ [67,68]
Figure 3 Human endogenous retroviruses and their
hypothetical role in psoriasis. During HIV-1 infection, HIV-1 tat
protein acts as a trans-acting factor activating HERV’s long terminal
repeat (LTR). Stimulation of the trans-activation region (TAR) by its
interaction with the HIV-1 tat protein activates transcription.
Subsequently, exogenous retroviruses trigger an immune response,
and HERV-encoded proteins are recognized as self-antigens
(molecular mimicry) awakening a cellular-based autoimmune
phenomenon.
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sively above the nipple line [46] (Figure 2G).
Histology of the lesions shows follicular spongiosis
and folliculocentric mixed inflammatory infiltrate of
eosinophils, lymphocytes, hystiocytes, mast cells and
neutrophils around the outer root sheaths of hair folli-
cles [84] (Figure 2H).
EF is typically seen when CD4
+ cell count drops below
300 cells/mm
3 [85]. The suggested pathogenesis involves
a Th2 cytokine response to an unknown antigen (Pityr-
osporum ovale or Demodex folliculorum) [86], with
elevation of interleukin-4, interleukin-5 and the chemo-
kines RANTES (chemokine that mediates chemotaxis,
recruits eosinophils in the allergic late phase reaction)
and Eotaxin ( a chemoattractant for eosinophils, baso-
phils, mast cells and Th-2 lymphocytes) [7] (Figure 1).
Additionally, EF has also been described as an autoim-
mune reaction to the sebocyte [87].
A clinical entity, called necrotizing eosinophilic folli-
culitis, describes the spectrum of the disease in AIDS
patients who are atopic and develop ulceration, nodules
and dermal follicular necrosis [88]. Its pathogenesis sug-
gests an unrepressed Th2-type response to epicutaneous
stimuli in atopic individuals [88]. EF has been inter-
preted as a marker of HIV-1 infection for subjects who
have a high risk of developing opportunistic infections
[89], but it is also part of the immune reconstitution
syndrome when antiretroviral therapy is started [90].
Miscellaneous disorders
Other dermatologic manifestations have been associated
primarily with HIV-1 infection. Photodermatitis [91],
vitiligo and other pigmentary alterations of the skin
[92], porphyria cutanea tarda (PCT) [93], granuloma
anulare [94], pityriasis rubra pilaris [95], pemphigus vul-
garis and many other autoimmune reactions [96] have
been reported, but a clear association between the
pathogenesis of each of these disorders and the retro-
virus has not yet been established.
In the case of PCT, the presence of this disorder in
HIV-1/AIDS patients is thought to be secondary to a
defect in the hepatic cytochrome oxidase system [97].
This impairment could lead to an aberration in por-
phyrin metabolism and subsequently cause porphyria
[97]. Predisposing factors for the development of PCT
in HIV-1/AIDS patients are co-infection with hepatitis
C, alcohol abuse and hepatotoxic drug consumption
[93]. Major precautions have to be taken by caregivers
of these individuals as HIV-1 virions have been isolated
from blister fluid of PCT/HIV-1 patients [98].
Cutaneous drug reactions (CDRs) are often reported
in AIDS patients as directly related to HIV-1 infection
[99]. CDRs include a wide spectrum of disorders that
range from mild morbilliform reactions (~70%) to
Stevens-Johnson syndrome/toxic epidermal necrolysis
(7.3%) [99]. Their direct connection with HIV-1 is based
on two major changes associated with the infection: the
induction of defective metabolic pathways; and the mod-
ification in the immune function. HIV-1 infection
induces the production of interferons [99]. Subse-
quently, interferons increase the production of xanthine
oxidase, a superoxide that destroys the hepatic cyto-
chrome, P-450. Modifications on this drug-metabolizing
system enhance the toxic potential of many drugs [100].
Moreover, CDRs may also be stimulated by the T cell
imbalance produced by HIV-1 depletion of CD4+ cells
[99,101].
Stevens-Johnson syndrome (SJS), a cell-mediated
immune reaction, is more prevalent in HIV-1-positive
individuals than in their seronegative counterparts [99].
SJS is commonly seen as the consequence of a multi-
drug regimen that includes sulfa-drugs and antiretroviral
agents (e.g., nevirapine) [101,102]. Nevertheless, there
are a number of case reports that support the concept
of erythema multiforme as the presenting manifestation
of HIV-1 seroconversion [103-105]. Yet there is not
enough data to support a cause-effect relationship.
Small animal models for the study of HIV-1-related
primary cutaneous complications
Due to the high costs of non-human primate research,
transgenic rodent models represent the best approach to
reproduce pathologies seen in HIV-1 infection. In the
late 1990s, a couple of rodent models seemed to be pro-
mising tools to study the pathogenesis of HIV-1-
associated complications. These models transgenically
expressed the human marker, CD4 (hCD4), and the co-
receptor, hCXCR4, or the chemokine receptor, hCCR5,
respectively [106,107]. As promising as they could be,
numerous drawbacks were observed in these mice,
which included a lack of CD4
+ T cells binding to HIV-1
protein gp120, and subsequent lack of infectivity and
replication in the target cells [108].
From that experience, some non-infectious transgenic
murine models of HIV-1 with deleted gag and pol genes
were created. These HIV-1 Tg mice developed patholo-
gic conditions similar to their human counterparts with
HIV-1 infection; including the development of skin dis-
orders [109,110]. Such lesions were reported as prolif-
erative epidermal lesions accompanied by progressive
ulceration of the epidermis, or described as benign
lesions resembling papillomas, Kaposi’s sarcoma-like
lesions [14] or B cell lymphomas [111].
However, the data generated from these models evi-
denced several failures, including numerous post-entry
blocks due to inefficient tat transactivation. The defi-
ciency in Tat function was further correlated with its
lack of interaction with a gene product encoded on
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cyclin T does not interact functionally with tat, a fact
that makes it a non-functional viral promoter [112] and
consequently an unreliable model.
I n2 0 0 1 ,w ed e v e l o p e da nH I V - 1T gr a tt h a ts h o w e d
similar pathology to that expressed in HIV-1/AIDS
patients, and that overcame some of the problems
encountered in the Tg mouse [109].
Unlike mice carrying the same transgene, efficient
viral gene expression occurred in lymph nodes, spleen,
thymus and blood, suggesting a functional tat [109].
Additionally, the generation of an HIV-1 transgenic rat
appears to be a much better model both from the stand-
point of size and that rat-derived cells are permissive for
post-entry steps in the HIV-1 replication cycle. As
recently reported, the HIV-1 Tg rat developed skin
lesions in about 30% of the littermates [10]. Histologi-
cally, these lesions exhibited epidermal hyperplasia and
hyperkeratosis, with an intense lymphocytic infiltrate
and epidermal necrosis. Additionally, while the Tg rat
showed the same pattern of serum cytokines seen in
HIV-1/AIDS patients with a shift from Th1 to Th2 cyto-
kines [113], analysis of the lesional skin showed a mixed
cytokine profile [10]. In fact, none of the HIV-1 Tg
rodent models currently available resembles precisely
the pathology observed in AIDS patients.
However, while the non-infectious HIV-1 rodent mod-
els did not reproduce similar skin pathology to that
observed in AIDS patients, a recently reported huma-
nized murine model might recapitulate the immunologi-
cal phenomena seen in the skin of HIV-1-infected
individuals. In this model, non-obese diabetic mice with
severe combined immunodeficiency are implanted with
human fethal thymic and liver organoids, followed by
sub-lethal irradiation, and then transplanted with human
CD34
+ stem cells derived from fetal livers [114]. These
chimeric humanized mice show infiltration of stem cell-
derived leukocytes (T and B lymphocytes) in different
organs, including the liver, lung, gastrointestinal tract
and grafted human skin [115]. Lately, this model has
become a valuable tool to evaluate intra-rectal HIV-1 pri-
mary infection and anti-retroviral drug efficacy [114,116].
Moreover, there is another animal model that might
be promising for the study of the pathogenesis of psoria-
s i sa n dH E R V s[ 1 1 7 ] .T h i sm o u s es t r a i nw a so r i g i n a l l y
reported to have a natural mutation known as flaky skin
(fsn) mutation, localized in chromosome 17. This muta-
tion induces a pathologic conditions that resembles
psoriasiform dermatitis, accompanied by anaemia,
hyper-IgE and anti-dsDNA autoantibodies similar to
those detected in systemic lupus erythematosus [117].
The cause of this mutation is due to the insertion of an
endogenous retrovirus (early transposon class) into
intron 14 of the Tetratricopeptide repeat domain
7 gene. Further studies on this animal might confirm a
definite role of HERVs in the pathogenesis of psoriasis.
Conclusions
The pathogenesis of most HIV-1-related complications
is not completely understood due to the complexity of
this novel virus and to the drawbacks associated with
their reproduction in controlled settings. Skin disorders
are not the exception; the high prevalence of cutaneous
manifestations related to this disease encourages us to
search for more reliable explanations of the pathogen-
esis of these disorders.
Secondary complications related to HIV-1 are becom-
ing less prevalent as HAARTi sm o r ew i d e l ya v a i l a b l e
[ 2 9 ] .H o w e v e r ,n oc h a n g ei np r e v a l e n c ei ss e e ni nt h e
primary complications. Moreover, such disorders as
acne, staphylococcal infections, and erythema nodosum
are being seen more frequently as part of the immune
reconstitution syndrome [4].
All of the primary dermatologic complications in HIV-
1-infected patients are also seen in immunocompetent
patients. Such conditions as atopic dermatitis, psoriasis,
and seborrheic dermatitis are extremely common der-
matologic problems expressed in the general population;
however, the direct role of the virus in the pathogenesis
of these manifestations is still to be discovered. Note-
worthy, the use of infectious and non-infectious HIV-1
Tg rodent models has failed to reproduce immunologi-
cal phenomena and similar morphological skin disorders
observed in AIDS patients. Better animal models, which
may include humanized rodents, might represent a
more suitable approach for the study of the pathogen-
esis of HIV-1-related disorders and the development of
more effective forms of treatment.
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